| Similar Articles |
|---|
 |
The Motley Fool
March 25, 2008
Brian Orelli |
Biovail Hit by a Slow-Moving Truck Biovail finally settles with the SEC, more than four years after the agency started an investigation into the drugmaker.   |
The Motley Fool
May 7, 2009
Brian Orelli |
Derailed and Built to Stay That Way Investors aren't happy with Biovail's plan to get back on track. |
The Motley Fool
September 23, 2008
Brian Orelli |
Extended Look at an Extended-Release Drug The FDA is still investigating Teva's generic Wellbutrin XL. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma. |
The Motley Fool
March 16, 2007
Billy Fisher |
Challenge Awaits Biovail The company's popular Wellbutrin XL will be facing generic competition soon. Biovail is currently trading 36% below its 52-week high. |
The Motley Fool
October 29, 2007
Brian Orelli |
The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note. |
The Motley Fool
December 11, 2006
Brian Lawler |
Biovail Gives Investors the Cash Regardless of lower forward estimates, though, it's nice to see a mature biotech rewarding shareholders, and if Biovail can sustain its dividend over the long run, it will be by far the highest-yielding mid-cap pharma stock. |
The Motley Fool
November 13, 2006
Brian Lawler |
Biovail Is Getting Cheap One of the drugmaker's products could face generic competition in the next year. Investors, take note. |
The Motley Fool
November 21, 2007
Brian Orelli |
Depression Hits Biovail An FDA decision on Biovail's depression drug could be another six months away. |
The Motley Fool
February 28, 2011
Cindy Johnson |
Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
June 6, 2005
Stephen D. Simpson |
"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
The Motley Fool
April 7, 2010
Rick Steier |
Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity. |
The Motley Fool
April 7, 2010
Brian Orelli |
Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
The Motley Fool
January 19, 2010
Brian Orelli |
Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious. |
The Motley Fool
August 3, 2004
Jeff Hwang |
Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%. |
The Motley Fool
November 7, 2008
Brian Orelli |
Teva's Steady Growth Generic-drug maker Teva Pharmaceuticals has been a good defensive play during the severe downturn in the market. |
The Motley Fool
September 22, 2009
Robert Steyer |
Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge. |
The Motley Fool
April 25, 2011
Sean Williams |
Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
The Motley Fool
October 13, 2009
Dave Mock |
A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst. |
The Motley Fool
March 28, 2006
Charly Travers |
"60 Minutes" Blew It The venerable news show stumbles in its coverage of short selling. While some CEOs might draw attention away from their businesses' performance by invoking the short-seller boogeyman, rational investors should resist that distraction and focus on the crystal-clear fundamentals. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
The Motley Fool
July 30, 2008
Brian Orelli |
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. |
BusinessWeek
March 14, 2005
Gene G. Marcial |
The Allure Of Impax "Impax' pipeline is impressive. So it's valuable as a stand-alone or as a buyout," says Robin Manners West of New Mexico's State Investment Council. |
The Motley Fool
March 4, 2005
Rich Duprey |
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails. |
The Motley Fool
December 26, 2007
Brian Orelli |
Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute. |
The Motley Fool
February 17, 2010
Brian Orelli |
This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it. |
The Motley Fool
December 9, 2010
Brian Orelli |
Here Comes Another Oral MS Drug Good for Teva, bad for the rest. |
The Motley Fool
September 9, 2010
Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. |
The Motley Fool
February 4, 2008
Chuck Saletta |
Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker. |
The Motley Fool
July 25, 2005
Stephen D. Simpson |
Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note. |
The Motley Fool
October 5, 2011
Dan Caplinger |
Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future. |
The Motley Fool
September 30, 2011
Brian Orelli |
When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
May 11, 2011
Jared Cummans |
Wednesday's ETF to Watch: iShares MSCI Israel Fund Teva Pharmaceuticals releases earnings today. |
Chemistry World
October 5, 2012
Phillip Broadwith |
Teva pulls generic antidepressant The move was prompted by an FDA investigation into whether the generic version (Budeprion XL, made by Impax and marketed by Teva) is truly therapeutically equivalent to the branded medicine (Wellbutrin XL). |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool
August 12, 2011
Matt Koppenheffer |
3 Stocks I Bought During the Panic With Mr. Market lowering prices on nearly everything, I did some shopping. |
The Motley Fool
May 5, 2009
Brian Orelli |
Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet. |
The Motley Fool
August 15, 2006
David Meier |
Invest the Right Way Today The right way to invest is to take advantage of mispriced opportunities in the market. And to avoid a value trap, investors need to work to identify a company's competitive advantage and estimate its margin of safety. |
The Motley Fool
December 1, 2009
Brian Orelli |
Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor. |
The Motley Fool
March 31, 2008
Rich Duprey |
Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
The Motley Fool
March 3, 2010
Brian Orelli |
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Biovail Last? Stop obsessing about the science. |
